Current paradigms of cancer chemoprevention

Cancer chemoprevention has been continually evolving ever since the term was coined in the 70s. From the original approaches of identifying chemopreventive agents from the dietary constituents based on the epidemiological data to the current status of adapting them from the molecular targets, significant understanding of cancer as a disease and its possible prevention has been achieved. The identification of the chemopreventive agent from a complex mixture of natural product extracts involves numerous steps including bioassay guided fractionation; evaluation of the extracts, fractions and isolated new chemicals selectively using in vitro and in vivo experimental models; and understanding the mechanism of their action. This in turn provides identification of the molecular target for the parent drug and a basis for the synthesis of more effective, nontoxic analogs. A chemopreventive agent by definition needs to be nontoxic, since it is expected to be consumed by healthy people that may be at a higher risk of developing cancer. This makes a case for these agents to be evaluated as possible adjuvant chemotherapeutic agents. It is expected that more selective delivery methods to the target organs to eliminate toxicity and use of chemopreventive agents as adjuvant chemotherapeutic agent using personalized approaches will be the next steps for chemoprevention.

Anahtar Kelimeler:

Chemoprevention, biomarkers, prevention trials, discovery of chemopreventive agents

Current paradigms of cancer chemoprevention

Keywords:

Chemoprevention, biomarkers, prevention trials, discovery of chemopreventive agents,

PDF

___

Aggarwal BB, Gupta SC, Sung B (2013). Curcumin: an orally bioavailable blocker of TN and other pro-inflammatory biomarkers. Br J Pharmacol 169: 1672–1692.
Almouazen E, Bourgeois S, Jordheim LP, Fessi H, Briançon S (2013). Nano-encapsulation of vitamin D3 active metabolites for application in chemotherapy: formulation study and in vitro evaluation. Pharm Res 30: 1137–1146.
Ankerst DP, Till C, Boeck A, Goodman PJ, Tangen CM, Thompson IM (2013). Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology 82: 1076–1081.
Banin-Hirata BK, Oda JM, Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA (2014). Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers 2014: 513158.
Bilecová-Rabajdová M, Birková A, Urban P, Gregová K, Durovcová E, Mareková M (2013). Naturally occurring substances and their role in chemo-protective effects. Eur J Public Health 21: 213–219.
Cabrespine-Faugeras A, Bayet-Robert M, Bay JO, Chollet P, Barthomeuf C (2010). Possible benefits of curcumin regimen in combination with taxane chemotherapy forhormone- refractory prostate cancer treatment. Nutr Cancer 62: 48–53.
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ et al. (2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381: 1827–1834.
Dunn BK, Richmond ES, Minasian LM, Ryan AM, Ford LG (2010). A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr Cancer 62: 896–918.
Funakoshi T, Lee CH, Hsieh JJ (2014). A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev 40: 533–547.
Giangreco AA, Vaishnav A, Wagner D, Finelli A, Fleshner N, Van der Kwast T, Vieth R, Nonn L (2013). Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev Res (Phila) 6: 483–494.
Grandhi BK, Thakkar A, Wang J, Prabhu S (2013). A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res (Phila) 6: 1015– 1025.
Gullett NP, Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ, Kucuk O (2010). Cancer prevention with natural compounds. Semin Oncol 37: 258–281.
Ishikawa H, Mutoh M, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S et al. (2014). The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 63: 1755–1759.
Jordan C (2014). Tamoxifen as the first targeted long term adjuvant therapy for breast cancer. Endocr Relat Cancer 21: R235–246.
Khan N, Bharali DJ, Adhami VM, Siddiqui IA, Cui H, Shabana SM, Mousa SA, Mukhtar H (2014). Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 35: 415–423.
Khuda-Bukhsh AR, Das S, Saha SK (2014). Molecular approaches toward targeted cancer prevention with some food plants and their products: inflammatory and other signal pathways. Nutr Cancer 66: 194–205.
Kocic B, Kitic D, Brankovic S (2013). Dietary flavonoid intake and colorectal cancer risk: evidence from human population studies. J BUON 18: 34–43.
Kinghorn AD, Chai HB, Sung CK, Keller WJ (2011)The classical drug discovery approach to defining bioactive constituents of botanicals. Fitoterapia 82: 71–79.
Labarge MA, Parvin B, Lorens JB (2014). Molecular deconstruction, detection, and computational prediction of microenvironment- modulated cellular responses to cancer therapeutics. Adv Drug Deliv Rev 69–70: 123–131.
Lee JH, Khor TO, Shu L, Su ZY, Fuentes F, Kong AN (2013). Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol Ther 137: 153–171.
Limaverde-Sousa G, Sternberg C, Ferreira CG (2014). Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single- target to broad-spectrum agents. Cancer Treat Rev 40: 548–557.
Lippman SM (2013). Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31: 2942–2962.
Mahmoud AM, Yang W, Bosland MC. (2014) Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol 140: 116–132.
Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, Muzzio M, Mehta RG (2013). Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One 8: e65113.
Mehta RR, Katta H, Kalra A, Patel R, Gupta A, Alimirah F, Murillo G, Peng X, Unni A, Muzzio M et al. (2013b). Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells. Clin Exp Metastasis. 30: 855–866.
Mehta RG, Murillo G, Naithani R, Peng X (2010). Cancer chemoprevention by natural products: how far have we come? Pharm Res 27: 950–961.
Mehta RG, Naithani R, Huma L, Hawthorne M, Moriarty RM, McCormick DL, Steele VE, Kopelovich L (2008). Efficacy of chemopreventive agents in mouse mammary gland organ culture (MMOC) model: a comprehensive review. Curr Med Chem 15: 2785–2825.
Mehta RG, Peng X, Alimirah F, Murillo G, Mehta R (2012a). Vitamin D and breast cancer: emerging concepts. Cancer Lett 334: 95–100.
Mehta RG, Pezzuto JM. (2002) Discovery of cancer preventive agents from natural products: from plants to prevention. Curr Oncol Rep 4: 478–486.
Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG (2008). Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 15: 1044–1071.
Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, Chang G, Li X, Li Q, Wang S et al. (2014). MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 9: e96228.
Peng X, Vaishnav A, Murillo G, Alimirah F, Torres KE, Mehta RG (2010). Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J Cell Biochem 110: 1324–1333.
Saleiro D, Murillo G, Lubahn DB, Kopelovich L, Korach KS, Mehta RG (2010). Enhanced induction of mucin-depleted foci in estrogen receptor {beta} knockout mice. Cancer Prev Res (Phila) 3: 1198–1204.
Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, Philip PA, Li Y (2013). Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res 3: 465–477.
Smith HW, Muller WJ (2013). Transgenic mouse models—a seminal breakthrough in oncogene research. Cold Spring Harb Protoc 2013: 1099–1108.
Sporn MB, Dunlop NM, Newton DL, Smith JM (1976). Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35: 1332–1338.
Steward WP, Brown K (2010). Cancer chemoprevention: a rapidly evolving field Br J Cancer 109: 1–7.
Szliszka E, Krol W (2011). The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)- induced apoptosis for cancer chemoprevention. Eur J Cancer Prev 20: 63–69.
Temraz S, Mukherji D, Shamseddine A (2013). Potential targets for colorectal cancer prevention. Int J Mol Sci 14: 17279–17303.
Uray IP, Brown PH (2011). Chemoprevention of hormone receptor- negative breast cancer: new approaches needed. Recent Results Cancer Res 188: 147–162.
Van Asten K, Neven P, Lintermans A, Wildiers H, Paridaens R (2014). Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocr Relat Cancer 21: R31–49.
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L et al. (2013). Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention. Mol Clin Oncol 1: 215–219.
Wang R, Guo L, Wang P, Yang W, Lu Y, Huang Z, Tang C (2013). Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr Pharm Des 19: 115–125.
Wattenberg LW (1992). Inhibition of carcinogenesis by minor dietary constituents. Cancer Res 52 (Suppl): 2085s–2091s.
Wiehle R, Lantvit D, Yamada T, Christov K (2011). CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis. Cancer Prev Res (Phila) 4: 414–424.
William WN, Heymach JV, Kim ES, Lippman SM (2009). Molecular targets for cancer chemoprevention. Nat Rev Drug Disco 8: 213–225.
Wouters A, Boeckx C, Vermorken JB, Van den Weyngaert D, Peeters M, Lardon F (2013). The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors. Curr Pharm Des 19: 907–917.
Ye JJ, Cao J (2014). MicroRNAs in colorectal cancer as markers and targets: recent advances. World J Gastroenterol 20: 4288–4299.